Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors

Uyoga, Sophie, Adetifa, Ifedayo M. O., Karanja, Henry K., Nyagwange, James, Tuju, James, Wanjiku, Perpetual, Aman, Rashid, Mwangangi, Mercy +31 more·2021·Science
DOI 10.1126/science.abe1916

Cited by (290)

Items 201–290 of 290

  1. Seroepidemiology of SARS-CoV-2 in a cohort of pregnant women and their infants in Uganda and Malawi
    Lauren Hookham, Liberty Cantrell, Stephen Cose, Bridget Freyne, Luis Aaron Gadama, Esther Imede, Kondwani Kawaza, Samantha Lissauer, Phillipa Musoke, Victoria Nankabirwa et al. · 2024 · PLoS ONE
  2. SARS-CoV-2 Seroprevalence and Profiles Among Convalescents in Sichuan Province, China
    Lijun Jane Zhou, Li Cheng, Huiping Yang, Heng Yuan, Ming Pan, Xiuwei Cheng, Chongkun Xiao, Xiaoyan Su, Yuanfang Zhu, Jianan Xu et al. · 2021 · Frontiers in Public Health
  3. Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021
    Patrick K. Munywoki, Godfrey Bigogo, Carolyne Nasimiyu, Alice Ouma, George Aol, Clifford Oduor, Samuel Rono, Joshua Auko, George O. Agogo, Ruth Njoroge et al. · 2023 · Gates Open Research
  4. Lower SARS-CoV-2 Seroprevalence among Cancer Patients in Sub-Saharan Africa
    For Yue Tso, Salum J. Lidenge, John R. Ngowi, Phoebe B. Peña, Ashley A. Clegg, Owen Ngalamika, Chacha John Mwita, Julius David Mwaiselage, Charles A. Wood · 2022 · Journal of Clinical Medicine
  5. Seroprevalence of SARS-CoV-2 among Blood Donors in the Republic of Congo
    Serge Oscar Mokono, Edwige Paola Chancelle Louanga Nanitelamio, Chaldam Jespère Mbani, Aude Tabapika, Taty Taty, Nina Esther Ngoyi Ontsira, Donatien Moukassa · 2022 · Open Journal of Blood Diseases
  6. Seroprevalence of Immunoglobulin G against measles and rubella over a 12-year period (2009 – 2021) in Kilifi, Kenya and the impact of the Measles-Rubella (MR) Vaccine campaign of 2016
    2025
  7. Seroprevalence of SARS-CoV-2 antibodies and demographic predictors among asymptomatic individuals in Osun State, Nigeria
    2025
  8. Profile: The Kenya Multi-Site Serosurveillance (KEMIS) collaboration
    2024
  9. Seroprevalence of SARS-CoV-2 antibodies in Republic of Congo, February 2022
    Gilbert Ndziessi, Fabien Roch Niama, Gilius Axel Aloumba, Jethro Massala Peya, Joseph Axel Ngatse, Ngoyomi Ryschel, Ange Clauvel Niama, N’Kaya Tobi, Antoine Loussambou, Jean Medard Kankou et al. · 2023 · Epidemiology and Infection
  10. SARS-CoV-2 Antibody Seroprevalence in Jakarta, Indonesia
    2022
  11. Genomic epidemiology of SARS-CoV-2 infections in The Gambia, March 2020 to Jan 2022
    Abdoulie Kanteh, Haruna S. Jallow, Jarra Manneh, Bakary Sanyang, Mariama A. Kujabi, Sainabou Laye Ndure, Sheikh Jarju, Alhagie Papa Sey, Dabiri Damilare K, Yaya Bah et al. · 2022 · medRxiv
  12. Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali
    Fara Wagbo Temessadouno, J.-G. Ndong, Etienne Gignoux, Yves Coppieters, Alhassane Ba, Youssouf Diam Sidibe, Aminata Daou, Nada Malou, Idrissa Compaore, Tidiani Fane et al. · 2023 · PLOS Global Public Health
  13. Prevalence of antibodies against SARS-CoV-2 among pregnant women in Norway during the period December 2019 through December 2020
    2022
  14. The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
    2022
  15. Determinants of long-term SARS-CoV-2 immune responses in asymptomatic-to-moderate COVID-19 patients in sub-Saharan Africa
    Víctor López de Rioja, Odin Goovaerts, Marta Vidal, Prof John Amuasi, Anthony Afum-Adjei Awuah, Christian M Kahusu, Placide Mbala Kingebeni, Ritha Nyembu Kibambe, Matthieu Tshitamba, Chirac Kazadi et al. · 2026 · BMC Medicine
  16. Controlling the first wave of the COVID–19 pandemic in Malawi: results from a panel study
    Jethro Banda, Albert Lazarous Nkhata Dube, Sarah Brumfield, Amelia Catharine Crampin, Georges Reniers, Abena Serwaa Amoah, Stéphane Helleringer · 2021 · medRxiv
  17. Prevalence assessment adjusted for laboratory test performance using an example of the COVID-19 serological tests
    Ekaterina A. Krieger, A M Grjibovski, Постоев Виталий Александрович · 2022 · Экология человека
  18. Spatiotemporal prevalence of COVID-19 and SARS-CoV-2 variants in Africa
    Li-Ping Gao, Can-Jun Zheng, Ting-Ting Tian, Alie Brima Tia, Michael K. Abdulai, K. Xiao, Cao Chen, Dong-Lin Liang, Q. Shi, Zhi-Guo Liu et al. · 2025 · Frontiers in Public Health
  19. Seroprevalence of SARS‐CoV‐2 Antibodies and Associated Factors in Bamako, Mali: A Population‐Based Cross‐Sectional Study in September 2022
    Bourama Traoré, Merepen A. Guindo, Drissa S Konate, Fousseyni Kané, Nathan C. Incandela, Abdouramane Traoré, Salimata Kanté, Mariam Sidibé, Bourama Keïta, Fatoumata Kassé et al. · 2024 · Influenza and Other Respiratory Viruses
  20. SARS-CoV-2 antibody prevalence, correlates, and access to harm reduction services among people who inject drugs living with and without HIV and their partners in Kenya
    2023
  21. Culture, health and well-being sit in places. Impact of COVID-19 on the African Society: geo-anthropological perspectives
    2020
  22. Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study
    John Kimotho, Yiakon Sein, Shahin Sayed, Reena Shah, Kennedy Mwai, Mansoor Noorali Saleh, Perpetual Wanjiku, Jedidah K. Mwacharo, James Nyagwange, Henry Karanja et al. · 2023 · Wellcome Open Research
  23. Morbidity and mortality burden of COVID-19 in rural Madagascar: results from a longitudinal cohort and nested seroprevalence study
    A. Garchitorena, L. T. Rasoloharimanana, R. J. Rakotonanahary, M. Evans, A. Miller, K. Finnegan, Laura F. Cordier, Giovanna Cowley, B. Razafinjato, Marius Randriamanambintsoa et al. · 2023 · medRxiv
  24. Leveraging social network topology could improve the efficiency of SARS-CoV-2 epidemic control strategies in resource-limited contexts
    Michelle Evans, Tanjona Ramiadantsoa, Kayla M. Kauffman, James W. Moody, Charles L. Nunn, Jean Yves Rabezara, Prisca Raharimalala, Toky Maheriniaina Randriamoria, Voahangy Soarimalala, Georgia Titcomb et al. · 2022 · medRxiv
  25. Determinants of having severe acute respiratory syndrome coronavirus 2 neutralizing antibodies in Egypt
    Amira S. El Refay, Sara Hussein Mahmoud, Mohamed A. Marouf, Mokhtar R. Gomaa, Ahmed El Taweel, Noura M. Abo Shama, Mohamed GabAllah, Soha M. Abd El Dayem, Ahmed Kandeil, Ahmed Mostafa et al. · 2021 · Influenza and Other Respiratory Viruses
  26. Epidemic trends of SARS-CoV-2 associated with immunity, race, and viral mutations
    Yasuhiko Kamikubo, Toshio Hattori, Atsushi Takahashi · 2020
  27. Seroprevalence and risk factors for SARS-CoV-2 infection in middle-sized cities of Burkina Faso: A descriptive cross-sectional study
    2024
  28. Prevalence of SARS-CoV-2 Antibodies from a one-year National Serosurveillance of Kenyan Blood Transfusion Donors
    2021
  29. Changes to household income in a Kenyan informal settlement during COVID-19
    Anna Tompsett, Aaron Baum, Vera Bukachi · 2021 · medRxiv
  30. Comparative reconstruction of SARS-CoV-2 transmission in three African countries using a mathematical model integrating immunity data
    Bechir S. Naffeti, Walid Ben Aribi, Amira Kebir, Maryam Diarra, Matthieu J. Schoenhals, Inès Vigan-Womas, Koussay Dellagi, Slimane Ben Miled · 2023 · IJID Regions
  31. Anti-SARS-CoV-2 Antibody Development over Four Years in Blood Donors
    Christoph Niederhauser, Nadja Widmer, Caroline Tinguely, Franziska Suter‐Riniker, Stefano Fontana, Andreas S. Buser, Sophie Waldvogel, Jutta Thierbach, Max Züger, Peter Gowland · 2025 · Viruses
  32. Seroprevalence of IgG Anti-SARS-CoV-2 among Voluntary Blood Donors in Dubai: Demographic and Risk Factors
    2021
  33. Dynamics of SARS-CoV-2 exposure in Malawian blood donors: a retrospective seroprevalence analysis between January 2020 and February 2021
    2021
  34. High Seroprevalence of SARS-COV-2 Antibody before Covid-19 Vaccination in Nigerian Communities
    D O Olaleye, M Aminu, BA Olusola, TO Segun, AO Faneye, Adewale Victor Opayele, Elizabeth Chibuzo Odeh, M Sarki, MD Dairo, Adeniyi Francis Fagbamigbe et al. · 2022 · International Archives of Public Health and Community Medicine
  35. Controlling the first wave of the COVID–19 pandemic in Malawi: Results from a multi-round study
    Jethro Banda, Albert Lazarous Nkhata Dube, Sarah Brumfield, Amelia Catharine Crampin, Georges Reniers, Abena Serwaa Amoah, Stéphane Helleringer · 2024 · PLOS Global Public Health
  36. Seroprevalence of antibodies against SARS-CoV-2 in the school community in Campo Grande, state of Mato Grosso do Sul, Brazil, October 2021–November 2022
    Claudia Stutz, Daniel Máximo Corrêa Alcântara, Camila Maria dos Santos et al. · 2024 · Frontiers in Immunology
  37. Effects of the COVID-19 pandemic on hospital admissions and inpatient mortality in Kenya: a retrospective cohort study
    Morris Ondieki Ogero, Lynda Isaaka, Ruth Khadembu Lucinde, Livingstone Mumelo, Henry Gathuri, Dennis Kimego, Teresiah Njoroge, George Mbevi, Conrad W. Wanyama, Mark Otiende et al. · 2024 · Wellcome Open Research
  38. Alternative epidemic indicators for COVID-19: a model-based assessment of COVID-19 mortality ascertainment in three settings with incomplete death registration systems
    Ruth McCabe, Charles Whittaker, Richard J. Sheppard, Nada Abdelmagid, Aljaile Ahmed, Israa Zain Alabdeen, Nicholas F. Brazeau, Abd Elhameed Ahmed Abd Elhameed, Abdulla Salem Bin-Ghouth, Arran Hamlet et al. · 2023 · medRxiv
  39. Association between wealth, insurance coverage, urban residence, median age and COVID-19 deaths across states in Nigeria
    Samuel Ayomikun Akinseinde, Samson Kosemani, Emmanuel Osuolale, Nina Cesare, Samantha Pellicane, Elaine Okanyene Nsoesie · 2023 · PLoS ONE
  40. Comparison of Infection-Induced SARS-CoV-2 Seroprevalence Across Large-Scale Residual Samples From Blood Donors, Commercial Laboratories, and Health Checkups in Japan, 2023
    2025
  41. Effects of the COVID-19 pandemic on hospital admissions and inpatient mortality in Kenya
    Morris Ondieki Ogero, Lynda Isaaka, Livingstone Mumelo, Dennis Kimego, Teresiah Njoroge, George Mbevi, Conrad W. Wanyama, Ruth Khadembu Lucinde, Henry Gathuri, Mark Otiende et al. · 2022 · medRxiv
  42. Blood type susceptibility to SARS-CoV-2 at a tertiary hospital in Accra, Ghana
    2025
  43. Analysis of SARS-CoV-2 antibody seroprevalence in Northern Ireland during 2020–2021
    Michelle K. Greene, Peter Smyth, Andrew R. English, Joseph B McLaughlin, Magda Bucholc, JANICE R. BAILIE, Julie McCarroll, Margaret McDonnell, Alison P. Watt, George Barnes et al. · 2024 · Heliyon
  44. An integrated rural health system baseline assessment of COVID-19 preparedness in Siaya Kenya
    Neema Chiwo Kaseje, Dan Kaseje, Kennedy Oruenjo, Penina Ocholla Odhiambo, Margaret Kaseje, Stephen Achola, Marcel Tanner, Andy Haines · 2021 · medRxiv
  45. A Serological Snapshot of COVID-19 Initial Stages in Israel by a 6-Plex Antigen Array
    Morly Fisher, Haim Levy, Ella Fatelevich, Yafa Afrimov, Amir Ben‐Shmuel, Ronit Rosenfeld, Tal Noy-Porat, Itai Glinert, Assa Sittner, Asaf Biber et al. · 2021 · Microbiology Spectrum
  46. Comparative performance of the InBios SCoV-2 Detect TM IgG ELISA and the in-house KWTRP ELISA in detecting SARS-CoV-2 spike IgG antibodies in Kenyan populations
    2024
  47. Kinetics of naturally induced binding and neutralizing anti-SARS-CoV-2 antibody levels and potencies among Kenyan patients with diverse grades of COVID-19 severity
    John Kimotho, Yiakon Sein, Shahin Sayed, Reena Shah, Kennedy Mwai, Mansoor Noorali Saleh, Perpetual Wanjiku, Jedidah K. Mwacharo, James Nyagwange, Henry Karanja et al. · 2022 · medRxiv
  48. Comparison of nucleocapsid and spike antibody ELISAs for determining SARS‐CoV‐2 seropositivity in Kenyan women and infants
    Carolyn S. Fish, Prestone Owiti, Emily R. Begnel, Hannah L. Itell, Ednah Ojee, Judith Adhiambo, Vincent Wayuga Ogweno, LaRinda A. Holland, Barbra A. Richardson, Adam K. Khan et al. · 2022 · Journal of Medical Virology
  49. Transmission of SARS-CoV-2 among underserved pastoralist communities in Kajiado County, Kenya: 2020–2022
    Zipporah Wanjiku Macharia, Brian Maina Ogoti, Magdaline Otieno, Pauline Gitonga, Angela M. Bosco‐Lauth, Marybeth C. Maritim, Esther Lemarkoko, Aggrey Keya, Joseph Sankok, George Chege Gitao et al. · 2024 · PLoS ONE
  50. Epidemiological Characteristics of Novel Coronavirus Disease (COVID-19) in Mombasa County, Kenya 2020
    2022
  51. Seroprevalence and demographic characteristics of SARS-CoV-2-infected residents of Kibera informal settlement during the COVID-19 pandemic in Nairobi, Kenya: a cross-sectional study
    2025
  52. Current challenges of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence studies among blood donors: A scoping review
    2021
  53. Prevalence of SARS-CoV-2 and co-occurrence/co-infection with malaria during the first wave of the pandemic (the Burkina Faso case)
    Diana López‐Farfán, Rakiswendé Serge Yerbanga, Marina Parres-Mercader, Manuela Torres‐Puente, Inmaculada Gómez-Navarro, Do Malick Soufiane Sanou, Adama Franck Yao, Jean‐Bosco Ouédraogo, Iñaki Comas, Nerea Irigoyen et al. · 2022 · medRxiv
  54. Sero-prevalence of SARS-CoV-2 antibodies in Ethiopia: Results of the National Population Based Survey, 2021
    Geremew Tasew, Saro Abdella, Birra Bejiga, Jemal Ayalew, Masresha Tessema, Feyiso Bati, Abraham Ali, Legesse Negash, Enyew Birru Tadese, Getachew Tollera et al. · 2025 · PLoS ONE
  55. Serosurveillance of Anti SARS-Cov-2 Antibodies among Essential Workers in Navi Mumbai - A Single Centre Study
    Ujwala M. Maheshwari, Jyotsna Sahai, Vivek Hebbar · 2021 · International Journal of Health Sciences and Research
  56. Restoring non-COVID-19 clinical research and surveillance in Oyo state, Nigeria during the SARS-CoV-2 pandemic
    Veronica Olatimbo Ogunleye, Okainemen P. Oluwalusi, Oluwafemi Akinyele Popoola, Aderemi Oludiran Kehinde, Olukemi A Adekanmbi, Ifiok Pius Udofia, Sarah Agbi, Ifeoluwa J. Akintayo, Jolaade J Ajiboye, Folasade Bamidele et al. · 2022 · Journal of Public Health in Africa
  57. Seroepidemiology of COVID-19 in pregnant women and their infants in Uganda and Malawi across multiple waves 2020-2022
    Lauren Hookham, Liberty Cantrell, Stephen Cose, Bridget Freyne, Luis Aaron Gadama, Esther Imede, Kondwani Kawaza, Samantha Lissauer, Phillipa Musoke, Vicki Nankabirwa et al. · 2023 · medRxiv
  58. Seroprevalence of Anti-SARS-CoV-2 Remained Extremely Low in Taiwan Until the Vaccination Program Was Implemented
    Yun‐Yuan Chen, Minhui Yang, Jou-Zhen Lai, Jen-Wei Chen, Yunlong Wang, Sheng‐Tang Wei, Sheng‐Mou Hou, Chien‐Jen Chen, Ho-Sheng Wu · 2023 · Open Forum Infectious Diseases
  59. COVID-19: SARS-CoV-2 Seroprevalence in a Blood Bank in Southern Brazil
    2022
  60. Modeling the health impact of increasing vaccine coverage and nonpharmaceutical interventions against coronavirus disease 2019 in Ghana
    2024
  61. Programmable DNA Nanostructure‐Based Sensing Platforms
    2026
  62. Immunity Gaps Across Age and Space to Tailor Immunization Activities in Zambia: Measles and Rubella Seroprevalence Using a National Biorepository
    2021
  63. Prevalence and Longevity of SARS-CoV-2 Antibodies in Healthcare Workers: A Single Center Study
    2020
  64. Seroprevalence and molecular detection of SARS-CoV-2 among apparently healthy healthcare workers and patients in a Nigerian tertiary hospital
    Rabi Ahmed Mahdi, Ahmad Hayatu, Umar Mohammed Hassan, Muhammad Sani Aliyu, M.H.I. Doko, Yahaya Usman · 2025 · BMC Infectious Diseases
  65. Examining the Impact of Increasing Vaccine Coverage and Nonpharmaceutical Interventions against Coronavirus Disease 2019 In Ghana using Mathematical Modeling
    Sylvia K. Ofori, Jessica S. Schwind, Kelly L. Sullivan, Gerardo Chowell, Benjamin John Cowling, Isaac Chun‐Hai Fung · 2022 · medRxiv
  66. Forte circulation silencieuse du SARS-CoV-2 au Burkina Faso : données de séroprévalence chez les donneurs de sang deux ans après le début de la pandémie à Bobo-Dioulasso
    Y. A. Nagalo, Hayazouma Hadiaratou Inès Hakiekou, Y. Sawadogo, Merci Muhigwa, D. Kabore, H. Kafando, A. Konkobo, Yétéma Dieudonné Yonli, Téwendé Céline Alice Rosine KOUMARE/KIBA, A. Ouedraogo · 2025 · Sciences de la Santé
  67. Very High Relative Seroprevalence of Anti--SARS-CoV-2 Antibodies Among Communities in Bangui, Central African Republic
    Alexandre Manirakiza, Christian Noël Malaka, Brice Martial Yambiyo, Saint Calvaire Henri Diémer, Jean de Dieu Longo, Joella Namseneï, Cathy Sandra Gomelle Coti-Reckoundji, Modeste Bouhouda, Marie Roseline Darnycka Bélizaire, Jean-Baptiste Roungou et al. · 2021 · medRxiv
  68. Assessing COVID-19 seroprevalence and vaccine uptake among women of reproductive-age in Zanzibar’s archipelago
    2025
  69. Neoadjuvant chemotherapy in women with triple-negative breast cancer: real world results from Western Kenya
    2026
  70. Влияние возраста на распространение новой коронавирусной инфекции в семьях, школах и во всём населении
    Edward Goldstein · 2020
  71. SARS-CoV-2 infection in female sex workers from Nairobi, Kenya early in the COVID-19 pandemic: Seroincidence and behavioural associations
    Su D. Yang, Freda Qi, Karen Colwill, Anne‐Claude Gingras, Tara S. Beattie, Joshua Kimani, Rupert Kaul · 2026 · PLoS ONE
  72. Assessing the Impact of SARS-CoV-2 Spike Mutations on Antibody Binding: A Comparative Assessment of the Wuhan and JN.1 Variants’ Full-Length Spikes in a Multiplex Luminex Assay
    Gerald Waweru, Ruth K. Nyakundi, Bernadette Kutima, Sharon Owuor, Gloria Konyino, John N. Gitonga, Doreen I. Lugano, Angela W. Maina, Jennifer Musyoki, Lucy B. Ochola et al. · 2025 · Viruses
  73. Differences in innate Intracellular viral suppression competencies may explain variations in morbidity and mortality from SARS-CoV-2 infection
    Shaibu Oricha Bello, Ehimario Uche Igumbor, Yusuf Deeni, Chinwe Lucia Ochu, Mustapha Ayodele Popoola · 2020 · medRxiv
  74. Epidemiology of natural immunity against COVID-19 in Benin
    2026
  75. Serum levels of immunoglobulin G and M antibodies against SARS-CoV-2 in asymptomatic individuals prior to COVID-19 vaccination in the Democratic Republic of Congo
    2026
  76. Pre-pandemic cross-reactive humoral immunity to SARS-CoV-2 in Africa: systematic review and meta-analysis
    John P. A. Ioannidis, Despina G. Contopoulos‐Ioannidis · 2022 · medRxiv
  77. SARS-CoV-2 infections averted by COVID-19 vaccination in Japan, 2021–2022: A combined surveillance and seroepidemiological analysis
    Shota Nishiyama, H. Nishiura · 2026 · Vaccine: X
  78. Characteristics of Symptomatic and Asymptomatic Patients With COVID-19 and Seroprevalence of anti-SARS-CoV-2 Antibodies in Zavidovići, Bosnia and Herzegovina
    2022
  79. Factors associated with mortality in patients diagnosed with COVID-19 in the Manzini Region, Eswatini, 2020-2021
    2025
  80. Cross-Country Assessment of Socio-Ecological Drivers of COVID-19 Dynamics in Africa: A Spatial Modelling Approach
    Kolawolé Valère Salako, Akoeugnigan Idelphonse Sode, Aliou Dicko, Ayédèguè Eustache Alaye, Martin Wolkewitz, Romain Glèlè Kakaï · 2024 · Stats
  81. Long-Term Assessment of the Persistence of Anti-SARS-CoV-2 Antibodies in Vaccinated Healthcare Workers in the Republic of Congo
    Jethro Massala Peya, Gilbert Ndziessi, Léadisaelle Hosanna Lenguiya · 2025 · Advances in Infectious Diseases
  82. Study of seroprevalence of antibodies to SARS-COV-2 among the healthy blood donors of Jammu region
    Neeti Dutt, Sushil Sharma, Meena Sidhu · 2022 · International Journal of Research in Medical Sciences
  83. SARS-CoV-2 Spread, Detection, and Dynamics in a Megacity in Latin America
    Rachid Laajaj, Camilo De Los Ríos, Ignacio Sarmiento-Barbieri, Danilo Aristizábal, Eduardo Behrentz, Raquel Bernal, Giancarlo Buitrago, Zulma M. Cucunubá, Fernando de la Hoz, Alejandro Gaviria et al. · 2021 · SSRN Electronic Journal
  84. Unveiling the Dynamics of the Omicron Variant: Prevalence, Risk Factors, and Vaccination Efficacy during the Third Wave of Covid-19 in Indonesia's Gowa Regency
    2023
  85. Preadmission testing for COVID-19 as a screening strategy: a retrospective chart review from a tertiary hospital in Kenya
    2022
  86. SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey
    2021
  87. Generation and Characterization of a variant of Thermostable Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV-RT) Enzyme
    Abdiaziz Ali Gosar, Josephine Kimani, Samson Muuo Nzou · 2024 · F1000Research
  88. Analysis of SARS-CoV-2 Ig seroprevalence in Northern Ireland
    Michelle K. Greene, Peter Smyth, Andrew R. English, Joseph McLaughlin, Magda Bucholc, JANICE R. BAILIE, Julie McCarroll, Margaret McDonnell, Alison P. Watt, George Barnes et al. · 2023 · medRxiv
  89. SARS-CoV-2 seroprevalence among pregnant women during the first three waves of the COVID-19 pandemic in southern Mozambique
    Esperança Sevene, Sónia Amós Maculuve, Corssino Tchavana, Anifa Valá, Lazaro M. Quimice, Salésio Macuácua, Carla Carrilho, Raquel Gonzalez, Tacilta Nhampossa, Clara Menéndez et al. · 2026 · BMC Pregnancy and Childbirth
  90. Comparative analysis of SARS-CoV-2 detection methods using stool, blood, and nasopharyngeal swab samples
    Marceline Adhiambo Oloo, Shehu Shagari Awandu, Benson Onyango, Richard Odongo Magwanga, Alfred O. Ochieng, Shirley Lidechi, Erick M. O. Muok, Stephen Munga, Benson B. A. Estambale · 2023 · Pan African Medical Journal